Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer

Peña, Francisco Ayala de la; J, Soler; Ivars, María Amparo Jimenez; Sánchez, Ana Fernández; Manzano, Esther Navarro; Barrio, Pilar de la Morena; García-Garré, Elisa; García‐Martínez, Elena; Zafra, Gema Marín; Aguilar, R. Salguero; García, Teresa

doi:10.1093/annonc/mdx365.046

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relationship between age and OS (n=37), PFS (n=7), and BCSS (n=3) was evaluated, with significant association reported in 46% (n=17), 29% (n=2), and 67% (n=2) of studies, respectively. 10 , 28 , 30 , 33 , 36 , 38 , 43 , 48 , 55 , 57 , 58 , 62 , 69 , 78 , 84 , 85 , 90–92 Among studies that found a significant association, increasing age was associated with worse OS, PFS, or BCSS. The time-point at which age data was collected in the study (whether age at diagnosis or at treatment initiation) was not reported in the majority of included studies.…”

Section: Resultsmentioning

confidence: 99%

“…The relationship between de novo mBC and OS (n=5), PFS (n=3), and BCSS (n=1) was evaluated, with a significant association reported in 100% (n=5), 67% (n=2), and 0% (n=0) of studies, respectively. 30 , 33 , 39 , 57 , 62 , 91 Four studies demonstrated longer OS in patients with mBC at diagnosis compared with recurrent breast cancer; 30 , 39 , 57 , 91 while one study reported shorter OS in patients with de novo mBC. 62 Similarly, one study showed longer PFS associated with patients with de novo mBC, 30 while another study showed a reverse relationship.…”

Section: Resultsmentioning

confidence: 99%

“… 30 , 33 , 39 , 57 , 62 , 91 Four studies demonstrated longer OS in patients with mBC at diagnosis compared with recurrent breast cancer; 30 , 39 , 57 , 91 while one study reported shorter OS in patients with de novo mBC. 62 Similarly, one study showed longer PFS associated with patients with de novo mBC, 30 while another study showed a reverse relationship. 33 …”

Section: Resultsmentioning

confidence: 99%

“…In three studies, increasing age was associated with worse OS. 57 , 62 , 69 Age groups compared across studies varied widely (eg, >50 vs ≤50 years, >65, or 50–64 vs 18–49 years). Among the different age group comparisons, age ≥50 years was the most common cut-off point, reported in six studies.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

Carter¹,

Mohanty²,

Stenger³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose Advanced breast cancer is a heterogeneous disease with several well-defined subtypes, among which, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) is most prevalent. Determination of HR and HER2 status influences prognosis and, thus, disease management. Although literature on these prognostic factors exist, especially in the early breast cancer setting, it remains unclear to what extent these factors can guide clinical decision-making in the advanced disease setting. Therefore, we sought to identify the strength and consistency of evidence for prognostic factors in patients with HR+/HER2– advanced breast cancer. Methods A systematic literature review (SLR) of the major electronic databases was conducted in November 2018 for primary research studies published since 2010. Endpoints of interest were tumor response, progression-free survival (PFS), overall survival (OS), and breast cancer-specific survival (BCSS). Results Seventy-nine studies were included wherein all patients were diagnosed with advanced breast cancer and ≥50% of the population were HR+/HER2–. OS was the most commonly assessed endpoint (n=67) followed by PFS (n=33), BCSS (n=5) and tumor response (n=3). The prognostic factors with strongest evidence of association with worse OS were negative progesterone receptor status, higher tumor grade, higher circulating tumor cell (CTC) count and higher Ki67 level, number of metastatic sites (eg multiple vs single) and sites of metastases (eg presence of liver metastases vs absence), shorter time to recurrence or progression to advanced breast cancer, poor performance status, prior therapy attributes in the early or metastatic setting (type of therapy, treatment line, response of prior therapy), and race (black vs white). The prognostic factors that had strongest evidence of association with PFS included CTC count, number and sites of metastases, and absence of prior therapy or higher lines of therapy in the early or metastatic setting. The directionality of association was consistent for all prognostic factors except between lymph node and OS, and de novo metastatic breast cancer and PFS. Conclusion Multiple disease, treatment, and patient-related prognostic factors impact survival, particularly OS, in patients with HR+/HER2– advanced breast cancer. Treatment outcomes can vary considerably due to these factors. Understanding poorer prognostic factors for patients can result in improved clinical decision-making.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

Carter¹,

Mohanty²,

Stenger³

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…La inflamación parece ser el telon de fondo para el desarrollo y la progresión tumoral, ya sea en la sangre o en el tejido tumoral. La relación entre neutrófilos y linfocitos conocido como Índice Neutrófilo-Linfocito (INL) se ha considerado un indicador de inflamación sistémica en muchos estudios clínicos actuales, incluyendo el cáncer gástrico (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) , en ausencia de infección obvia (25) .…”

Section: Introductionunclassified

Albumina e índice neutrófilo-linfocito como predictores de estadío tumoral en pacientes con cáncer gástrico

Huamán¹,

Cerna-Barco²,

Correa-López³

et al. 2020

RFMH

View full text Add to dashboard Cite

show abstract

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Patel

Luo

et al. 2019

Breast Cancer Res Treat

View full text Add to dashboard Cite

Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer

Cited by 4 publications

References 0 publications

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

Albumina e índice neutrófilo-linfocito como predictores de estadío tumoral en pacientes con cáncer gástrico

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Contact Info

Product

Resources

About